出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/04/09 08:29:22」(JST)[Wiki en表示]
|This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (August 2009)|
|Systematic (IUPAC) name|
|Oral, nasal spray|
|Metabolism||Hepatic (CYP1A2-mediated, to active metabolite)|
|Biological half-life||3 hours|
|Excretion||Renal (65%) and fecal (35%)|
|CAS Number||139264-17-8 Y|
|ATC code||N02CC03 (WHO)|
|Molar mass||287.357 g/mol|
Zolmitriptan is a selective serotonin receptor agonist of the 1B and 1D subtypes. It is a triptan, used in the acute treatment of migraine attacks with or without aura and cluster headaches.
Zolmitriptan is marketed by AstraZeneca with the brand names Zomig, Zomigon (Argentina, Canada & Greece), AscoTop (Germany) and Zomigoro (France). In 2008, Zomig generated nearly $154 million in sales.
AstraZeneca's U.S. patent on Zomig tablets expired on November 14, 2012, and its pediatric exclusivity extension expired on May 14, 2013. The patent in certain European countries has already expired too, and generic drug maker Actavis released a generic version in those countries, starting in March 2012.
- 1 Description
- 2 Indications
- 3 Contraindications and precautions
- 4 Adverse reactions
- 5 References
- 6 External links
Zolmitriptan is a synthetic tryptamine derivative and appears as a white powder that is partially soluble in water.
Zolmitriptan is used for the acute treatment of migraines with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine.
Zolmitriptan is available as a swallowable tablet, an oral disintegrating tablet, and a nasal spray, in doses of 2.5 and 5 mg. People who get migraines from aspartame should not use the disintegrating tablet (Zomig ZMT), which contains aspartame.
According to a study of healthy volunteers, food intake seems to have no significant effect on the effectiveness of Zolmitriptan in both men and women. 
Contraindications and precautions
Zolmitriptan should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's angina, or other significant underlying cardiovascular disease.
Zolmitriptan may increase blood pressure, it should not be given to patients with uncontrolled hypertension, should not be used within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide, and should not be administered to patients with hemiplegic or basilar migraine.
Concurrent administration of MAOI or use of zolmitriptan within 2 weeks of discontinuation of MAO-A inhibitor therapy is contraindicated.
The Zomig ZMT dissolvable pill contains aspartame, and should be avoided by anyone sensitive to that ingredient and by those suffering from phenylketonuria.
Rarely, serious cardiac events, including myocardial infarction, have been associated with zolmitriptan.
Reported minor adverse reactions include: hypesthesia, paresthesia (all types), warm and cold sensations, chest pain, throat and jaw tightness, dry mouth, dyspepsia, dysphagia, nausea, somnolence, vertigo, asthenia, myalgia, myasthenia and sweating.
Drug Interactions: see Zomig package insert for complete list: 
Following administration of cimetidine, the half-life and AUC of zolmitriptan and its active metabolites were approximately doubled (see CLINICAL PHARMACOLOGY in product pamphlet). Cimetidine (INN) (// or //) is a histamine H2-receptor antagonist that inhibits the production of acid in the stomach.
- PDF (332 KB). Drug Topics (May 26, 2009). Retrieved on August 25, 2009.
- Newman LC, Lipton RB (2001). "Migraine MLT-Down: An Unusual Presentation of Migraine in Patients With Aspartame-Triggered Headaches". Headache: the Journal of Head and Face Pain (abstract) 41 (9): 899–901. doi:10.1046/j.1526-4610.2001.01164.x.
- Emma J. Seaber, Richard W. Peck, Deborah A. Smith, John Allanson, Nanco R. Hefting, Jan J. van Lier, Frans A.E. Sollie, Johan Wemer, Jan H.G. Jonkman (1998). "The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers.". British Journal of Clinical Pharmacology (abstract) 46 (5): 433–439. doi:10.1046/j.1365-2125.1998.00809.x.
- MacGregor, E.A. (1998). "Zolmitriptan clinical studies". Drugs Today 34 (12): 1027–1033. doi:10.1358/dot.19220.127.116.117488. PMID 14743270.
- Zomig Information Site (USA)
- Efficacy of frovatriptan as compared to other triptans in migraine with aura.
- Evers S1, Savi L, Omboni S, Lisotto C, Zanchin G, Pinessi L.
- The journal of headache and pain.J Headache Pain.2015 Dec;16(1):514. doi: 10.1186/s10194-015-0514-8. Epub 2015 Apr 1.
- BACKGROUND: The treatment of migraine attacks with aura by triptans is difficult since triptans most probably are not efficacious when taken during the aura phase. Moreover, there are insufficient data from randomised studies whether triptans are efficacious in migraine attacks with aura when taken
- PMID 25916333
- SLCO1A2-MDCKII: a Promising in vitro System to Understand the Role of OATP1A2 in Blood Brain Barrier Drug Penetration.
- Liu H1, Yu N1, Lu S1, Ito S2, Zhang X2, Prasad B3, He E1, Lu X1, Li Y1, Wang F1, Xu H1, An G1, Unadkat JD3, Kusuhara H4, Sugiyama Y5, Sahi J6.
- Drug metabolism and disposition: the biological fate of chemicals.Drug Metab Dispos.2015 Apr 23. pii: dmd.115.064170. [Epub ahead of print]
- OATP1A2 has the potential to be a target for CNS drug delivery due to its luminal localization at the human blood-brain barrier and broad substrate specificity. We confirmed greater OATP1A2 mRNA expression in human brain relative to other tissues and report OATP1A2 expression comparable to BCRP and
- PMID 25908246
- Acute Migraine Treatment in Adults.
- Becker WJ1.
- Headache.Headache.2015 Apr 15. doi: 10.1111/head.12550. [Epub ahead of print]
- There are many options for acute migraine attack treatment, but none is ideal for all patients. This study aims to review current medical office-based acute migraine therapy in adults and provides readers with an organized approach to this important facet of migraine treatment. A general literature
- PMID 25877672
- 臨床神経学 53(11), 1131-1133, 2013
- NAID 130004505360
- 脳神経外科ジャーナル = Japanese journal of neurosurgery 21(10), 771-778, 2012-10-20
- NAID 10031131642
- 臨床神経学 52(11), 971-972, 2012
- NAID 130004505228